Design and synthesis of aminohydantoins as potent and selective human β-secretase (BACE1) inhibitors with enhanced brain permeability
Michael S. Malamas(Pearl River Community College), Menelas N. Pangalos(AstraZeneca (United Kingdom)), William R. Solvibile(Pfizer (United States)), Ping Zhou(Chengdu Women's and Children's Central Hospital), Dominick Quagliato(Pfizer (United States)), Erik Wagner(Princeton University), Kristi Fan, Jim Erdei(Pfizer (United States)), Koi Morris(Pfizer (United States)), Peter H. Reinhart(University of Massachusetts Amherst), Andrea Olland(Pfizer (United States)), Steve Jacobsen, Jim Turner(Pfizer (United States)), Albert J. Robichaud(Princeton University), David Riddell(Eli Lilly (United States))
Cited by 52
Related Papers
ApoE Promotes the Proteolytic Degradation of Aβ
|Neuron|2008|869
Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor
|Journal of Medicinal Chemistry|2012|460
Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels
|Journal of Neuroscience|2008|351
Compartmentalization of β-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts
|Current Biology|2001|302
The LXR agonist TO901317 selectively lowers hippocampal Aβ42 and improves memory in the Tg2576 mouse model of Alzheimer's disease
|Molecular and Cellular Neuroscience|2007|248